SCHEMBL784412

SCHEMBL784412

Cc1cc(N2CCC(N(C)C(=O)c3ccc4c(c3)[C@H](N(C(=O)c3cccc(F)c3Cl)C(C)C)CC4)CC2)nc(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAF1 P21675 3/20 0.37
CECR2 Q9BXF3 3/20 0.37
BRD9 Q9H8M2 3/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
USP30 Q70CQ3 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
TRPM8 Q7Z2W7 3/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
GBA1 P04062 1/20 0.32
AURKA O14965 1/20 0.32
GHSR Q92847 2/20 0.31
JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784535 0.92 TAF1 (0.41) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785607 0.90 TAF1 (0.39) TAF1CECR2BRD9TLR9TLR8
SCHEMBL784117 0.89 TAF1 (0.39) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785629 0.89 TAF1 (0.38) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785120 0.89 TAF1 (0.38) TAF1CECR2BRD9TLR9TLR8
SCHEMBL784120 0.89 TAF1 (0.40) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785389 0.86 F10 (0.38) SLC6A2SLC6A4SLC6A3HRH3TRPM8
SCHEMBL784896 0.86 TLR9 (0.38) TAF1CECR2BRD9TLR9TLR8
SCHEMBL784869 0.85 TAF1 (0.37) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785520 0.84 WDR5 (0.39) TAF1CECR2BRD9TLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US claimed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US claimed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 TAF1 2144/4885CECR2 888/4885BRD9 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.